In a prerecorded interview shown during a keynote session at the 2023 ISPE Annual Meeting & Expo, Tom Hartman, ISPE President and CEO, and Dr. Robert M. Califf discussed several far-ranging and important topics. Califf, the US Food and Drug Administration (FDA) 25th Commissioner is a recognized expert in cardiovascular medicine, health outcomes research,...
A fireside chat featuring Robert M. Califf, MD, FDA’s 25th Commissioner of Food and Drugs, and Thomas B. Hartman, President and CEO of ISPE kicked off the 2023 ISPE Annual Meeting & Expo. The following is a brief summary of the session. Look for complete coverage of the interview in an upcoming issue of Pharmaceutical Engineering® magazine.
Annex 1, the European Union’s revised GMP requirements for the manufacturing of sterile medicinal products, will take effect on 25 August 2023. In this panel, experts involved in industry’s commenting of the draft versions of Annex 1 offered background information on how the document was developed and answered questions on its implementation.
Opening the 2023 ISPE Europe Annual Conference on 8 May, Peter Twomey, Head of Inspections for the European Medicines Agency (EMA), offered a keynote address titled International Cooperation, Harmonization, and Reliance in GMP.
Emer Cooke, Executive Director of the European Medicines Agency (EMA), delivered an impactful keynote address at the 2023 ISPE Europe Annual Conference, held 8-10 May , in Amsterdam, The Netherlands. Cooke...
As we are all aware, the COVID-19 pandemic has had a unique, world-wide effect on the pharmaceutical industry as well as health authorities. At the height of the pandemic, and continuing as it appears to wane, health authorities have not been able not carry out normal, in-person inspections of pharmaceutical manufacturing sites. However, in the ”Age of Covid,” using the Internet and associated...
